NASDAQ:ORPN - Bioblast Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$10.78 -0.57 (-5.02 %)
(As of 03/24/2019 04:00 PM ET)
Previous Close$10.78
Today's Range$10.78 - $11.50
52-Week Range$6.16 - $30.00
Volume2,997 shs
Average VolumeN/A
Market Capitalization$4.53 million
P/E RatioN/A
Dividend YieldN/A
Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Its product candidate is Trehalose intravenous 90mg/mL solution, a protein stabilizer and autophagy enhancer for the treatment of patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company has a collaboration with Team Sanfilippo to evaluate Trehalose for the treatment of sanfilippo syndrome. Bioblast Pharma Ltd. was founded in 2012 and is headquartered in Tel Aviv, Israel.

Receive ORPN News and Ratings via Email

Sign-up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ORPN



Sales & Book Value

Annual SalesN/A
Book Value$7.56 per share



Market Cap$4.53 million
Next Earnings Date4/22/2019 (Estimated)
OptionableNot Optionable

Bioblast Pharma (NASDAQ:ORPN) Frequently Asked Questions

What is Bioblast Pharma's stock symbol?

Bioblast Pharma trades on the NASDAQ under the ticker symbol "ORPN."

When did Bioblast Pharma's stock split? How did Bioblast Pharma's stock split work?

Bioblast Pharma's stock reverse split on Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of Bioblast Pharma stock prior to the reverse split would have 13 shares after the split.

When is Bioblast Pharma's next earnings date?

Bioblast Pharma is scheduled to release their next quarterly earnings announcement on Monday, April 22nd 2019. View Earnings Estimates for Bioblast Pharma.

Has Bioblast Pharma been receiving favorable news coverage?

News headlines about ORPN stock have trended neutral recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bioblast Pharma earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the company's share price in the next several days.

Who are some of Bioblast Pharma's key competitors?

What other stocks do shareholders of Bioblast Pharma own?

Who are Bioblast Pharma's key executives?

Bioblast Pharma's management team includes the folowing people:
  • Dr. Dalia Megiddo M.B.A., Ph.D., M.D., MBA, Co-Founder, MD, CEO & Director (Age 67)
  • Dr. Warren W. Wasiewski, VP of R&D (Age 67)
  • Prof. Avizohar Argov M.D., Special Medical Advisor to the Chief Exec. Officer and Member of Scientific Advisory Board (Age 72)

How do I buy shares of Bioblast Pharma?

Shares of ORPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bioblast Pharma's stock price today?

One share of ORPN stock can currently be purchased for approximately $10.78.

How big of a company is Bioblast Pharma?

Bioblast Pharma has a market capitalization of $4.53 million.

What is Bioblast Pharma's official website?

The official website for Bioblast Pharma is

How can I contact Bioblast Pharma?

Bioblast Pharma's mailing address is PO Box 318, Tel-Aviv Is, 6100201. The biopharmaceutical company can be reached via phone at 972-3573-6632 or via email at [email protected]

MarketBeat Community Rating for Bioblast Pharma (NASDAQ ORPN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  201 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  308
MarketBeat's community ratings are surveys of what our community members think about Bioblast Pharma and other stocks. Vote "Outperform" if you believe ORPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel